πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7642355

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jan 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7632490

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7632847

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7629336

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Dec 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7622508

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. Β· Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7618630

Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin an

The Board of Regents of the University of Texas System Β· Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7608261

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7585868

Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists

The Regents of the University of California Β· Granted Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7585879

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7575742

Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7572920

Benzimidazole derivative and use as a II receptor antagonist

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7572893

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7569586

Compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor antagonist activit

Theravance, Inc. Β· Granted Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7569588

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7566718

Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist a

Pharmacopeia Drug Discovery, Inc. Β· Granted Tue Jul 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7560469

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jul 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7557126

Diphenylmethyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7557212

Tricyclic derivatives as LTD4 antagonists

Laboratories Almirall, S.A. Β· Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7550595

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7544358

Treatment of acute lung injury, fibrosis and metastasis with antagonists of Ξ±vΞ²6

The Regents of the University of California Β· Granted Tue Jun 09 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531500

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California Β· Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531172

Methods of treating diseases with a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531173

Ophthalmic composition of a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7528253

Compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor antagonist activit

Theravance, Inc. Β· Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted